Price of cancer care and its tax on quality of life

Journal of Oncology Practice

Volumn 14, Issue 2, 2018, Pages 69-71

  Tran, George ^a   Yousuf Zafar, S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; COPING BEHAVIOR; DRUG COST; HEALTH ECONOMICS; HUMAN; MALIGNANT NEOPLASM; QUALITY OF LIFE; REVIEW; TAX; ABSENTEEISM; CANCER THERAPY; EDITORIAL; EMOTION; FAMILY INCOME; FINANCIAL DEFICIT; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HOSPITALIZATION; MENTAL HEALTH; PHYSICAL CAPACITY; NEOPLASM;

HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; NEOPLASMS; QUALITY OF LIFE; TAXES;

EID: 85042037650     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2017.028498;     Document Type: Review

References (24)

1. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
2. Mailankody S, Prasad V: Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncol 1:539-540, 2015
3. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: Associations with medication and medical utilization and spending and health. JAMA 298:61-69, 2007
4. Bernard DS, Farr SL, Fang Z: National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 29:2821-2826, 2011
5. Ramsey SD, Bansal A, Fedorenko CR, et al: Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980-986, 2016
6. Kent EE, Forsythe LP, Yabroff KR, et al: Are survivors who report cancer-related fi-nancialproblemsmorelikelytoforgoordelaymedicalcare?Cancer119:3710-3717,2013
7. Kaisaeng N, Harpe SE, Carroll NV: Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm 20:669-675, 2014
8. Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18:381-390, 2013
9. Park J, Look KA: Relationship between objective financial burden and the health-related quality of life and mental health of cancer patients. J Oncol Pract 14: e113-e121, 2018
10. Fenn KM, Evans SB, McCorkle R, et al: Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 10:332-338, 2014
11. Zafar SY, McNeil RB, Thomas CM, et al: Population-based assessment of cancer survivors’ financial burden and quality of life: A prospective cohort study. J Oncol Pract 11:145-150, 2015
12. Delgado-Guay M, Ferrer J, Rieber AG, et al: Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist 20:1092-1098, 2015
13. Kale HP, Carroll NV: Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122:283-289, 2016
14. Lathan CS, Cronin A, Tucker-Seeley R, et al: Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 34:1732-1740, 2016
15. Folkman S, Lazarus RS: An analysis of coping in a middle-aged community sample. J Health Soc Behav 21:219-239, 1980
16. Folkman S, Lazarus RS, Dunkel-Schetter C, et al: Dynamics of a stressful encounter: Cognitive appraisal, coping, and encounter outcomes. J Pers Soc Psychol 50: 992-1003, 1986
17. Franks HM, Roesch SC: Appraisals and coping in people living with cancer: A meta-analysis. Psychooncology 15:1027-1037, 2006
18. Thomsen TG, Rydahl-Hansen S, Wagner L: A review of potential factors relevant to coping in patients with advanced cancer. J Clin Nurs 19:3410-3426, 2010
19. Head B, Harris L, Kayser K, et al: As if the disease was not enough: Coping with the financial consequences of cancer. Support Care Cancer https://doi.org/10.1007/ s00520-017-3918-y [epub ahead of print on October 11, 2017]
20. Alexander GC, Casalino LP, Meltzer DO: Patient-physician communication about out-of-pocket costs. JAMA 290:953-958, 2003
21. Stump TK, Eghan N, Egleston BL, et al: Cost concerns of patients with cancer. J Oncol Pract 9:251-257, 2013
22. Zafar SY, Chino F, Ubel PA, et al: The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care 21:607-615, 2015
23. Mehnert A, Hartung TJ, Friedrich M, et al: One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Psychooncology, 2017 https://doi.org/10.1002/pon.4464 [epub ahead of print on May 31, 2017]
24. de Souza JA, Yap BJ, Wroblewski K, et al: Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123:476-484, 2017